Gliclazide improves blood glucose control by stimulating insulin secretion from pancreatic β-cells and is widely used in the treatment of T2D (Al-Omary, 2017; Ibrahim and Hassan, 2018). This evidence concerns the gene INS and type 2 diabetes mellitus.